EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network

Laura Rozenblum iD, Damien Galanaud, Caroline Houillier, Carole Soussain, Amandine Baptiste, Lisa Belin, Véronique Edeline, Philippe Naggara, Marine Soret, Valérie Causse-Lemercier, Lise Willems, Sylvain Choquet und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06334-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Laura Rozenblum und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France. Laura.rozenblum@gmail.com. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Central Nervous System Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Primary central nervous system lymphoma (PCNSL) incidence is rising among elderly patients, presenting challenges due to poor prognosis and treatment-related toxicity risks. This study explores the potential of combining [18F]fluorodeoxyglucose ([18F]FDG) PET scans and multimodal MRI for improving management in elderly patients with de novo PCNSL. METHODS: Immunocompetent patients over 60 years with de novo PCNSL were prospectively enrolled in a multicentric study between January 2016 and April 2021. Patients underwent brain [18F]FDG PET-MRI before receiving high-dose methotrexate-based chemotherapy. Relationships between extracted PET (metabolic tumor volume (MTV), sum of MTV for up to five lesions (sumMTV), metabolic imaging lymphoma aggressiveness score (MILAS)) and MRI parameters (tumor contrast-enhancement size, cerebral blood volume (CBV), cerebral blood flow (CBF), apparent diffusion coefficient (ADC)) and treatment response and outcomes were analyzed. RESULTS: Of 54 newly diagnosed diffuse large B-cell PCNSL patients, 52 had positive PET and MRI with highly [18F]FDG-avid and contrast-enhanced disease (SUVmax: 27.7 [22.8-36]). High [18F]FDG uptake and metabolic volume were significantly associated with low ADCmean values and high CBF at baseline. Among patients, 69% achieved an objective response at the end of induction therapy, while 17 were progressive. Higher cerebellar SUVmean and lower sumMTV at diagnosis were significant predictors of complete response: 6.4 [5.7-7.7] vs 5.4 [4.5-6.6] (p = 0.04) and 5.5 [2.1-13.3] vs 15.9 [4.2-19.5] (p = 0.01), respectively. Two-year overall survival (OS) was 71%, with a median progression-free survival (PFS) of 29.6 months and a median follow-up of 37 months. Larger tumor volumes on PET or enhanced T1-weighted MRI were significant predictors of poorer OS, while a high MILAS score at diagnosis was associated with early death (< 1 year). CONCLUSION: Baseline cerebellar metabolism and sumMTV may predict response to end of chemotherapy in PCNSL. Tumor volume and MILAS at baseline are strong prognostic factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Magnetic Resonance ImagingCentral Nervous System NeoplasmsPositron-Emission TomographyLymphomaHumansAgedMaleFemaleAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

Outcome analysisPET/MRIPrimary central nervous system lymphoma[18F]FDG

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France. Laura.rozenblum@gmail.com.
  • Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France. Laura.rozenblum@gmail.com.
  • Sorbonne Université, INSERM, CNRS, Laboratoire d'Imagerie Biomédicale, LIB, Paris, France.
  • Department of Neuroradiology, Groupe Hospitalier Pitié-Salpêtrière, APHP, Sorbonne Université, Paris, France.
  • Deparrment of Neurology 2 Mazarin, APHP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Paris, France.
  • Department of Hematology, Institut Curie, Site Saint-Cloud and INSERM U932 Institut Curie, Université PSL, 75005, Paris, France.

ORCID-Profile: Laura Rozenblum

Zitieren

APA

Rozenblum, L., Galanaud, D., Houillier, C., Soussain, C., Baptiste, A., Belin, L., Edeline, V., Naggara, P., Soret, M., Causse-Lemercier, V., Willems, L., Choquet, S., Ursu, R., Hoang-Xuan, K., & Kas, A. (2023). [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06334-w

Vancouver

Rozenblum L, Galanaud D, Houillier C, Soussain C, Baptiste A, Belin L, et al. [18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06334-w

BibTeX
@article{Rozenblum2023,
  author = {Rozenblum, Laura and Galanaud, Damien and Houillier, Caroline and Soussain, Carole and Baptiste, Amandine and Belin, Lisa and Edeline, Véronique and Naggara, Philippe and Soret, Marine and Causse-Lemercier, Valérie and Willems, Lise and Choquet, Sylvain and Ursu, Renata and Hoang-Xuan, Khê and Kas, Aurélie},
  title = {[18F]FDG PET-MRI provides survival biomarkers in primary central nervous system lymphoma in the elderly: an ancillary study from the BLOCAGE trial of the LOC network},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06334-w}
}
Kostenlos starten →